Table 2.
Comparisons between patients with statin-induced lung injury diagnosed at our institute and reported in the English literature
| Variable | Our patients (N=4) | Reported patients (N=12) | p Value |
|---|---|---|---|
| Age, years | 67.5±20.7 | 69.7±8.8 | 0.953 |
| Gender (male/female) | 4/0 | 7/5 | 0.181 |
| Duration of statin treatment, months | 4.0±5.4 | 41.0±36.0 | 0.030 |
| Symptoms | |||
| Dyspnoea | 4 (100.0) | 11 (91.7) | 0.750 |
| Cough | 2 (50.0) | 7 (58.3) | 0.608 |
| Fever | 4 (100.0) | 2 (16.7) | 0.008 |
| Laboratory findings | |||
| Leucocytosis | 1/4 (25.0) | 1/2 (50.0) | 0.600 |
| Elevated CK level | 1/3 (33.3) | 2/3 (66.7) | 0.500 |
| Impaired LFT | 1/3 (33.3) | 2/2 (100.0) | 0.300 |
| HRCT findings | |||
| Alveolar infiltrates | 4 (100.0) | 7 (58.3) | 0.181 |
| Consolidation | 3 (75.0) | 1 (8.3) | 0.027 |
| GGO | 4 (100.0) | 5 (41.7) | 0.069 |
| Unspecified | 0 (0) | 2 (16.7) | 0.550 |
| Interstitial infiltrates | 1 (25.0) | 1 (8.3) | 0.450 |
| Fibrosis | 0 (0) | 6 (50.0) | 0.115 |
| Pleural changes | 2 (50.0) | 1 (8.3) | 0.136 |
| Spirometry | |||
| Restrictive | 2/3 (66.7) | 4/7 (57.1) | 0.667 |
| Obstructive | 0/3 (0) | 3/7 (42.9) | 0.292 |
| DLCO, % of predicted | 42.3±2.9 | 33.7±11.3 | 0.373 |
| BALF cytology | |||
| Foamy macrophages | 4/4 (100.0) | 0/6 (0) | 0.005 |
| Neutrophils, > 3% | 1/4 (25.0) | 4/6 (66.7) | 0.262 |
| Lymphocytes, > 20% | 1/4 (25.0) | 1/6 (16.7) | 0.667 |
| Eosinophils, > 0.5% | 1/4 (25.0) | 4/6 (66.7) | 0.044 |
Data are expressed as mean±SD or n (%).
BALF, bronchoalveolar lavage fluid; CK, creatinine kinase; DLCO, carbon monoxide diffusion capacity; GGO, ground glass opacity; HRCT, high-resolution CT; LFT, liver function test.